Category Archives: OTC

Terra Tech Corp. (TRTC: OTCQX U.S.) | UPDATE

IRVINE, CA–(Marketwired – January 01, 2018) – Terra Tech Corp. (OTCQX: TRTC) (“Terra Tech” or the “Company”), a vertically integrated cannabis-focused agriculture company, today announced that it has received State of California Temporary Authorization to distribute and retail cannabis, and expects to receive authorizations to cultivate and manufacture cannabis for California’s adult-use and medical markets, effective January 1, 2018. Terra Tech plans to commence adult-use cannabis sales to the California market immediately through its Blüm retail dispensaries located in Oakland and Santa Ana.

Terra Tech first started selling medical cannabis products to patients in California through its Blüm dispensary in Oakland. In anticipation of adult-use sales, the Company opened a second Blüm retail location in Santa Ana, California in September, 2017 and is currently constructing a Blüm dispensary in San Leandro, which is expected to open to the public in early 2018. The Company is also expanding its cultivation facilities through its ‘Craft Cultivation’ model, and has signed two craft cultivators, based in Honeydew and Salinas, to ramp production of the Company’s brand of premium cannabis. The Company’s IVXX cannabis is grown and harvested under the safest and most beneficial conditions, free of toxic pesticides, harmful molds and chemical residues. All products are rigorously tested and certified to the highest standards of potency and purity.

“California has the oldest medical cannabis program in the nation and has the largest population out of any state in America. This adult-use license allows us to significantly expand our potential customer base in California beyond the medical market,” commented Derek Peterson, Chief Executive Officer of Terra Tech. “Terra Tech is one of only a handful of companies that has been issued this adult-use license in time for the Jan 1st start date. We believe this first mover advantage will enable us to grow our brand and gain traction with new customers in what is expected to be the nation’s largest cannabis market. Over the past several months we have worked diligently to expand both our retail presence and our cultivation facilities to prepare us for this exciting opportunity and we look forward to capitalizing on our progress to grow sales and build value for shareholders.”

Once issued the State of California’s Temporary Authorization to conduct medical and adult cannabis retail sales, manufacturing, cultivation and distribution will be valid for 120 days and may be extended for an additional 90 days. This transition period, from January 1, 2018 through July 1, 2018, allows for existing operators to apply for their annual permits and affords the industry an opportunity to align all business operations with new state requirements. During this time period existing operators with local approval are authorized to retail the inventory on hand as of December 31, 2017, so long as it is appropriately labeled and in controlled packaging. Terra Tech is required to submit further information and documents related to each of its respective business entities to the State of California in order to secure annual adult-use and medical licenses, including but not limited to incorporation documents, business operational plans, financial information, and leadership/executive information, labor peace agreements for operations with more than 20 employees, along with proof of local approval to operate.

To be added to the Terra Tech email distribution list, please email TRTC@kcsa.com with TRTC in the subject line.

About Terra Tech

Terra Tech Corp. (OTCQX: TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Blüm’s retail and medical cannabis facilities provide the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions as well as premium cannabis to the adult-use market in Nevada. Blüm offers a broad selection of cannabis products including; flowers, concentrates and edibles through its Oakland, CA and multiple Nevada locations. IVXX, Inc. is a wholly-owned subsidiary of Terra Tech that produces cannabis-extracted products for regulated medical cannabis dispensaries throughout California and medical and adult-use dispensaries in Nevada. The Company’s wholly-owned subsidiary, Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as ShopRite, Walmart, Winn-Dixie, Raley’s, Meijer, Kroger, Stop Shop and others nationwide. Terra Tech’s MediFarm LLC subsidiaries are focused on medical and adult-use cannabis cultivation and permitting businesses throughout Nevada.

For more information about Terra Tech Corp visit: http://www.terratechcorp.com/
For more information about IVXX visit: http://ivxx.com/
For more information about Blüm Nevada visit: http://letsblum.com
For more information about Blüm Oakland visit: http://blumoak.com/
Visit us on Facebook @ https://www.facebook.com/terratechcorp/timeline
Follow us on Twitter @terratechcorp
For more information about Edible Garden visit: http://www.ediblegarden.com/
Visit Edible Garden on Facebook @ https://www.facebook.com/ediblefarms?fref=ts
Visit IVXX on Facebook @ https://www.facebook.com/ivxxbrand?fref=ts

Cautionary Language Concerning Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Terra Tech Corp.’s filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to Terra Tech Corp.’s (i) product demand, market and customer acceptance of its equipment and other goods, (ii) ability to obtain financing to expand its operations, (iii) ability to attract qualified sales representatives, (iv) competition, pricing and development difficulties, (v) ability to integrate GrowOp Technology Ltd. into its operations as a reporting issuer with the Securities and Exchange Commission, and (vi) general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Terra Tech Corp.’s website does not constitute a part of this release.

Article source: http://www.otcmarkets.com/stock/TRTC/news?id=179232

FirstAtlantic Financial Holdings Inc. (FFHD: OTCQX U.S. Premier) | National Commerce Corporation Announces Closing of Merger with FirstAtlantic Financial Holdings, Inc.

BIRMINGHAM, Ala., Jan. 01, 2018 (GLOBE NEWSWIRE) — National Commerce Corporation (Nasdaq:NCOM) (“NCC”), the parent company of National Bank of Commerce (“NBC”), headquartered in Birmingham, Alabama, announced today the completion of the merger of FirstAtlantic Financial Holdings, Inc. (OTCQX:FFHD) (“FirstAtlantic”), the parent company of FirstAtlantic Bank, with and into NCC.  Concurrently with the merger, FirstAtlantic Bank merged with and into NBC, but its offices will continue to operate under the “FirstAtlantic Bank” trade name, and its management team will continue with NBC.

“We are extremely pleased to partner with the team at FirstAtlantic,” said Richard Murray, IV, President and Chief Executive Officer of NCC.  “Mitch Hunt and his team have built a great bank, and we believe they are an excellent fit for our company.  We welcome the clients, shareowners and employees of FirstAtlantic Bank to NCC.  We look forward to working together with Mitch and Paul Grube as they lead our growth in the greater Jacksonville market.”

Mitchell W. Hunt, Jr., President and Chief Executive Officer of FirstAtlantic, also spoke about the merger, saying, “We are very pleased to join with our friends at NCC, and we look forward to our partnership.  We believe we will be in an even better position to serve our customers as a part of National Bank of Commerce.”

In connection with the merger, Thomas H. Coley, a director of FirstAtlantic and FirstAtlantic Bank, has been appointed to the Boards of Directors of both NCC and NBC.  Coley has previously served as Executive Vice President, Head of Southern Banking Group at Wachovia Corporation and as Vice Chairman of SouthTrust Corporation.

Keefe, Bruyette Woods, Inc. acted as financial adviser to NCC, and Maynard, Cooper Gale, P.C. acted as its legal adviser.  FIG Partners, LLC acted as financial adviser to FirstAtlantic, and Troutman Sanders LLP acted as its legal adviser. 

About National Commerce Corporation

National Commerce Corporation (Nasdaq:NCOM), a Delaware corporation, is a financial holding company headquartered in Birmingham, Alabama.  Substantially all of the operations of National Commerce Corporation are conducted through the company’s wholly owned subsidiary, National Bank of Commerce.  National Bank of Commerce currently operates seven full-service banking offices in Alabama, twenty-two full-service banking offices in central and northeast Florida (including under the trade names United Legacy Bank, Reunion Bank of Florida, Patriot Bank and FirstAtlantic Bank) and two full-service banking offices in the Atlanta, Georgia metro area (including under the trade names Private Bank of Buckhead, Private Bank of Decatur and PrivatePlus Mortgage).  National Bank of Commerce provides a broad array of financial services for commercial and consumer customers.

Additionally, National Bank of Commerce owns a majority stake in Corporate Billing, LLC, a transaction-based finance company based in Decatur, Alabama that provides factoring, invoicing, collection and accounts receivable management services to transportation companies and automotive parts and service providers throughout the United States and parts of Canada.

National Commerce Corporation files periodic reports with the U.S. Securities and Exchange Commission (the “SEC”).  Copies of its filings may be obtained through the SEC’s website at www.sec.gov or at www.nationalbankofcommerce.com.  More information about National Commerce Corporation and National Bank of Commerce may be obtained at www.nationalbankofcommerce.com.

Forward-Looking Statements

Certain statements contained in this press release that are not statements of historical fact constitute forward-looking statements for which NCC claims the protection of the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995 (the “Act”), notwithstanding that such statements are not specifically identified as such.  In addition, certain statements may be contained in NCC’s future filings with the SEC, in press releases and in oral and written statements made by NCC or with NCC’s approval that are not statements of historical fact and that constitute forward-looking statements within the meaning of the Act.  Words such as “believes,” “anticipates,” “expects,” “intends,” “targeted,” “continue,” “remain,” “will,” “should,” “may” and other similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.

Forward-looking statements (including oral representations) involve risks and uncertainties that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.  These risks and uncertainties include difficulties, delays and unanticipated costs in integrating NBC’s and FirstAtlantic Bank’s businesses or realizing expected cost savings and other benefits; business disruptions as a result of the integration of the merging organizations, including possible loss of customers; diversion of management time to address transaction-related issues; and changes in asset quality and credit risk as a result of the merger.  These risks also include a number of factors related to the business of NCC and the banking business generally, including various risks to stockholders of not receiving dividends; risks to NCC’s ability to pursue growth opportunities; various risks to the price and volatility of NCC’s common stock; NCC’s ability to incur additional financial obligations in the future; risks associated with NCC’s possible pursuit of future acquisitions; economic conditions in NCC’s current service areas, including the new service areas created by the merger; system failures; losses of large customers; disruptions in relationships with third-party vendors; losses of key management personnel and the inability to attract and retain highly qualified management and personnel in the future; changes in the extensive governmental legislation and regulations governing banking; high costs of regulatory compliance; the impact of legislation and regulatory changes, including changes in the tax laws, on the banking industry; and liability and compliance costs regarding banking regulations.

Forward-looking statements made by NCC in this press release or elsewhere speak only as of the date on which the statements were made.  You are advised to read the risk factors in NCC’s most recently filed Annual Report on Form 10-K and subsequent filings with the SEC, which are available through the website maintained by the SEC at www.sec.gov or by accessing information available at www.nationalbankofcommerce.com.  New risks and uncertainties arise from time to time, and it is impossible for NCC to predict these events or how they may affect it or its anticipated results.  NCC has no duty to, and does not intend to, update or revise the forward-looking statements in this press release, except as may be required by law.  In light of these risks and uncertainties, readers should keep in mind that any forward-looking statement made in this press release may not occur.  All information presented herein is as of the date of this release unless otherwise noted.

Contact Information

Richard Murray, IV                                                    
President and Chief Executive Officer                       
National Commerce Corporation                                                        
(205) 313-8100

Primary Logo

Article source: http://www.otcmarkets.com/stock/FFHD/news?id=179233

Collplant Holdings Ltd (CQPTY: OTCQB) | Completion of the Second Phase in Investment Agreement with ALPHA

Completion of the Second Phase in Investment Agreement with ALPHA

Jan 01, 2018

OTC Disclosure News Service

Ness-Ziona, Israel

This release includes additional documents. Select the link(s) below to view.

CollPlant – Private Investment Agreement – Second Phase Completion – English.pdf

Copyright © 2018 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/CQPTY/news?id=179231

Terra Tech Corp. (TRTC: OTCQX U.S.) | Terra Tech Corp. to Commence Adult Use Cannabis Sales in California on January 1, 2018

IRVINE, CA–(Marketwired – December 31, 2017) – Terra Tech Corp. (OTCQX: TRTC) (“Terra Tech” or the “Company”), a vertically integrated cannabis-focused agriculture company, today announced that it has received State of California Temporary Authorization to cultivate, non-volatile manufacture, distribute and retail cannabis for California’s adult-use and medical markets, effective January 1, 2018. Terra Tech plans to commence adult-use cannabis sales to the California market immediately through its Blüm retail dispensaries located in Oakland and Santa Ana.

Terra Tech first started selling medical cannabis products to patients in California through its Blüm dispensary in Oakland. In anticipation of adult-use sales, the Company opened a second Blüm retail location in Santa Ana, California in September, 2017 and is currently constructing a Blüm dispensary in San Leadro, which is expected to open to the public in early 2018. The Company is also expanding its cultivation facilities through its ‘Craft Cultivation’ model, and has signed two craft cultivators, based in Honeydew and Salinas, to ramp production of the Company’s IVXX-brand of premium cannabis. The Company’s IVXX cannabis is grown and harvested under the safest and most beneficial conditions, free of toxic pesticides, harmful molds and chemical residues. All products are rigorously tested and certified to the highest standards of potency and purity.

“California has the oldest medical cannabis program in the nation and has the largest population out of any state in America. This adult-use license allows us to significantly expand our potential customer base in California beyond the medical market,” commented Derek Peterson, Chief Executive Officer of Terra Tech. “Terra Tech is one of only a handful of companies that has been issued this adult-use license in time for the Jan 1st start date. We believe this first mover advantage will enable us to grow our brand and gain traction with new customers in what is expected to be the nation’s largest cannabis market. Over the past several months we have worked diligently to expand both our retail presence and our cultivation facilities to prepare us for this exciting opportunity and we look forward to capitalizing on our progress to grow sales and build value for shareholders.”

The state of California Temporary Authorization to conduct medical and adult cannabis retail sales, manufacturing, cultivation and distribution will be valid for 120 days and may be extended for an additional 90 days. This transition period, from January 1, 2018 through July 1, 2018, allows for existing operators to apply for their annual permits and affords the industry an opportunity to align all business operations with new state requirements. During this time period existing operators with local approval are authorized to retail the inventory on hand as of December 31, 2017, so long as it is appropriately labeled and in controlled packaging. Terra Tech is required to submit further information and documents related to each of its respective business entities to the State of California in order to secure annual adult-use and medical licenses, including but not limited to incorporation documents, business operational plans, financial information, and leadership/executive information, labor peace agreements for operations with more than 20 employees, along with proof of local approval to operate.

To be added to the Terra Tech email distribution list, please email TRTC@kcsa.com with TRTC in the subject line.

About Terra Tech

Terra Tech Corp. (OTCQX: TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Blüm’s retail and medical cannabis facilities provide the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions as well as premium cannabis to the adult-use market in Nevada. Blüm offers a broad selection of cannabis products including; flowers, concentrates and edibles through its Oakland, CA and multiple Nevada locations. IVXX, Inc. is a wholly-owned subsidiary of Terra Tech that produces cannabis-extracted products for regulated medical cannabis dispensaries throughout California and medical and adult-use dispensaries in Nevada. The Company’s wholly-owned subsidiary, Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as ShopRite, Walmart, Winn-Dixie, Raley’s, Meijer, Kroger, Stop Shop and others nationwide. Terra Tech’s MediFarm LLC subsidiaries are focused on medical and adult-use cannabis cultivation and permitting businesses throughout Nevada.

For more information about Terra Tech Corp visit: http://www.terratechcorp.com/
For more information about IVXX visit: http://ivxx.com/
For more information about Blüm Nevada visit: http://letsblum.com
For more information about Blüm Oakland visit: http://blumoak.com/
Visit us on Facebook @ https://www.facebook.com/terratechcorp/timeline
Follow us on Twitter @terratechcorp
For more information about Edible Garden visit: http://www.ediblegarden.com/
Visit Edible Garden on Facebook @ https://www.facebook.com/ediblefarms?fref=ts
Visit IVXX on Facebook @ https://www.facebook.com/ivxxbrand?fref=ts

Cautionary Language Concerning Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Terra Tech Corp.’s filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to Terra Tech Corp.’s (i) product demand, market and customer acceptance of its equipment and other goods, (ii) ability to obtain financing to expand its operations, (iii) ability to attract qualified sales representatives, (iv) competition, pricing and development difficulties, (v) ability to integrate GrowOp Technology Ltd. into its operations as a reporting issuer with the Securities and Exchange Commission, and (vi) general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Terra Tech Corp.’s website does not constitute a part of this release.

Article source: http://www.otcmarkets.com/stock/TRTC/news?id=179228

Terra Tech Corp. (TRTC: OTCQX U.S.) | Terra Tech Corp. to Commence Adult Use Cannabis Sales in California on January 1, 2018

IRVINE, CA–(Marketwired – December 31, 2017) – Terra Tech Corp. (OTCQX: TRTC) (“Terra Tech” or the “Company”), a vertically integrated cannabis-focused agriculture company, today announced that it has received State of California Temporary Authorization to cultivate, non-volatile manufacture, distribute and retail cannabis for California’s adult-use and medical markets, effective January 1, 2018. Terra Tech plans to commence adult-use cannabis sales to the California market immediately through its Blüm retail dispensaries located in Oakland and Santa Ana.

Terra Tech first started selling medical cannabis products to patients in California through its Blüm dispensary in Oakland. In anticipation of adult-use sales, the Company opened a second Blüm retail location in Santa Ana, California in September, 2017 and is currently constructing a Blüm dispensary in San Leadro, which is expected to open to the public in early 2018. The Company is also expanding its cultivation facilities through its ‘Craft Cultivation’ model, and has signed two craft cultivators, based in Honeydew and Salinas, to ramp production of the Company’s IVXX-brand of premium cannabis. The Company’s IVXX cannabis is grown and harvested under the safest and most beneficial conditions, free of toxic pesticides, harmful molds and chemical residues. All products are rigorously tested and certified to the highest standards of potency and purity.

“California has the oldest medical cannabis program in the nation and has the largest population out of any state in America. This adult-use license allows us to significantly expand our potential customer base in California beyond the medical market,” commented Derek Peterson, Chief Executive Officer of Terra Tech. “Terra Tech is one of only a handful of companies that has been issued this adult-use license in time for the Jan 1st start date. We believe this first mover advantage will enable us to grow our brand and gain traction with new customers in what is expected to be the nation’s largest cannabis market. Over the past several months we have worked diligently to expand both our retail presence and our cultivation facilities to prepare us for this exciting opportunity and we look forward to capitalizing on our progress to grow sales and build value for shareholders.”

The state of California Temporary Authorization to conduct medical and adult cannabis retail sales, manufacturing, cultivation and distribution will be valid for 120 days and may be extended for an additional 90 days. This transition period, from January 1, 2018 through July 1, 2018, allows for existing operators to apply for their annual permits and affords the industry an opportunity to align all business operations with new state requirements. During this time period existing operators with local approval are authorized to retail the inventory on hand as of December 31, 2017, so long as it is appropriately labeled and in controlled packaging. Terra Tech is required to submit further information and documents related to each of its respective business entities to the State of California in order to secure annual adult-use and medical licenses, including but not limited to incorporation documents, business operational plans, financial information, and leadership/executive information, labor peace agreements for operations with more than 20 employees, along with proof of local approval to operate.

To be added to the Terra Tech email distribution list, please email TRTC@kcsa.com with TRTC in the subject line.

About Terra Tech

Terra Tech Corp. (OTCQX: TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, and MediFarm LLC. Blüm’s retail and medical cannabis facilities provide the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions as well as premium cannabis to the adult-use market in Nevada. Blüm offers a broad selection of cannabis products including; flowers, concentrates and edibles through its Oakland, CA and multiple Nevada locations. IVXX, Inc. is a wholly-owned subsidiary of Terra Tech that produces cannabis-extracted products for regulated medical cannabis dispensaries throughout California and medical and adult-use dispensaries in Nevada. The Company’s wholly-owned subsidiary, Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as ShopRite, Walmart, Winn-Dixie, Raley’s, Meijer, Kroger, Stop Shop and others nationwide. Terra Tech’s MediFarm LLC subsidiaries are focused on medical and adult-use cannabis cultivation and permitting businesses throughout Nevada.

For more information about Terra Tech Corp visit: http://www.terratechcorp.com/
For more information about IVXX visit: http://ivxx.com/
For more information about Blüm Nevada visit: http://letsblum.com
For more information about Blüm Oakland visit: http://blumoak.com/
Visit us on Facebook @ https://www.facebook.com/terratechcorp/timeline
Follow us on Twitter @terratechcorp
For more information about Edible Garden visit: http://www.ediblegarden.com/
Visit Edible Garden on Facebook @ https://www.facebook.com/ediblefarms?fref=ts
Visit IVXX on Facebook @ https://www.facebook.com/ivxxbrand?fref=ts

Cautionary Language Concerning Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Terra Tech Corp.’s filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to Terra Tech Corp.’s (i) product demand, market and customer acceptance of its equipment and other goods, (ii) ability to obtain financing to expand its operations, (iii) ability to attract qualified sales representatives, (iv) competition, pricing and development difficulties, (v) ability to integrate GrowOp Technology Ltd. into its operations as a reporting issuer with the Securities and Exchange Commission, and (vi) general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Terra Tech Corp.’s website does not constitute a part of this release.

Article source: http://www.otcmarkets.com/stock/TRTC/news?id=179228

Safe-T Group Limited (SFTTY: OTCQB) | SAFE-T Receives Order from Global Cyber Solution Company

SAFE-T Receives Order from Global Cyber Solution Company

Dec 31, 2017

OTC Disclosure News Service

Herzeliya, Israel

This release includes additional documents. Select the link(s) below to view.

311217 – Safe-T – Cyber solution company.pdf

Copyright © 2017 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/SFTTY/news?id=179229

Safe-T Group Limited (SFTTY: OTCQB) | Safe-T Reports Conditional NIS570,000 Order from a Leading Israeli Manufacturer of Defense and Security Solutions

Safe-T Reports Conditional NIS570,000 Order from a Leading Israeli Manufacturer of Defense and Security Solutions

Dec 31, 2017

OTC Disclosure News Service

Herzeliya, Israel

This release includes additional documents. Select the link(s) below to view.

311217 – Safe-T – Israeli Defense provider2.pdf

Copyright © 2017 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/SFTTY/news?id=179230

Critical Outcome Technologies, Inc. (COTQF: OTCQB) | Critical Outcome Technologies Reports Fiscal 2018 Second Quarter Financial and Operating Results

LONDON, ONTARIO and BOSTON, MASSACHUSETTS–(Marketwired – Dec 29, 2017) – Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) (“COTI” or the “Company”) reported its financial and operating results today for the three- and six-month periods ended October 31, 2017. Recent highlights include:

Advanced the Phase 1 trial of COTI-2:

  • In August 2017, COTI completed the dose escalation portion of its Phase 1 trial of COTI-2 in gynecological malignancies, which showed that COTI-2 is generally safe and well-tolerated at doses up to 1.7 mg/kg;
  • In October 2017, COTI dosed the first patient in the expansion arm of its Phase 1 trial of COTI-2 in head and neck squamous cell carcinoma (HNSCC);
  • Subsequent to the reporting quarter, in November 2017, COTI announced pharmacokinetic (PK) data from the dose escalation portion of its Phase 1 trial of COTI-2 in gynecological malignancies, which showed that COTI-2 exhibited rapid absorption, long half-life and lack of long-term drug accumulation. These data support the potential for daily oral dosing and the continued development of COTI-2 as a potential treatment for patients;
  • Subsequent to the reporting quarter, in December 2017, COTI announced pharmacodynamic (PD) data and positive signals of efficacy from the dose escalation portion of its Phase 1 trial of COTI-2 in gynecological malignancies, which suggest COTI-2 may be a potentially efficacious treatment for patients. COTI concurrently announced it established a recommended Phase 2 dose of 1.0 mg/kg in ovarian cancer based on strong safety, tolerability and pharmacokinetic data;
  • Continued to analyze results from the gynecological arm of the trial.

Secured additional funding

  • In September and October 2017, COTI announced the close of the first and second tranches of a non-brokered private placement with accredited investors. The Company raised gross proceeds of approximately $2.1 million CAD. The funds will support the continued clinical development of COTI-2 in HNSCC.
  • Subsequent to the reporting quarter, the Company entered into an engagement with a U.S. investment bank in connection with proposed financing efforts in the U.S.

Reaffirmed identity as a clinical-stage pharmaceutical company:

  • During the quarter, the Company underwent a branding review recognizing its evolution from a technology-driven company to a clinical-stage pharmaceutical company. This led COTI to announce subsequent to the reporting quarter in December 2017, that shareholders approved a name change to Cotinga Pharmaceuticals. Cotinga refers to a diverse bird species in South and Central America, and symbolizes the potential for the Company’s cancer therapeutics to treat a wide spectrum of cancer patients.

“We are pleased to report we continued to make significant strides in the second quarter to advance the Phase 1 trial of COTI-2 and secure additional funding to support our clinical development programs,” said Alison Silva, President CEO. “The encouraging data readouts from the gynecological malignancies arm and the successful dosing of the first patient in our HNSCC expansion arm reinforce our confidence in COTI-2 as a potential treatment for a range of oncology indications. We are continuing with our financing efforts as we seek to carry out our mission in the year ahead as the newly-named Cotinga Pharmaceuticals, a clinical-stage pharmaceutical company advancing the development of cancer therapeutics to treat a wide spectrum of cancer patients.”

Upcoming Milestones

COTI-2:

  • Additional exploratory endpoint data from the dose escalation portion of the Phase 1 trial in gynecological malignancies expected in first quarter of 2018;
  • Initial safety readout from HNSCC expansion arm expected in second quarter of 2018;
  • Initiation of basket, combination and expansion studies in multiple oncology indications expected in 2018.

COTI-219:

  • Completion of GMP manufacturing and IND-enabling studies expected in 2018;
  • IND-filing expected in 2018.

Financial Results

The Company’s operational activities during the quarter were primarily focused on advancing the Phase 1 clinical trial of COTI-2 in gynecological malignancies and HNSCC.

For the three-months ended October 31, 2017, the Company incurred a net loss of $1.781 million, or $0.11 per share, compared to a net loss of $0.748 million, or $0.05 per share, for the three-months ended October 31, 2016. The increase in net loss during the three-month period is primarily due to a change in the fair value of the warrant liability, as a large non-cash valuation gain was recorded in the three-months ended October 31, 2016, thus reducing the loss in that period with no comparable valuation change occurring in the same period this year.

For the six-months ended October 31, 2017, the Company incurred a net loss of $2.023 million, or $0.13 per share, compared to a net loss of $3.063 million, or $0.21 per share, for the six-months ended October 31, 2016. The decrease in net loss during the six-month period is primarily due to a significant favorable swing in the valuation of the warrant liability.

There was no revenue for the three- and six-month periods ended October 31, 2017 or in the comparative periods in the year prior.

Operating expenses in the three- and six-month periods ended October 31, 2017 increased by $0.040 million and $0.224 million respectively over the same periods in the year prior, primarily due to increases in Research and Development (“RD”) expense and a decrease in investment tax credits earned. These increases were partially offset by a decrease in General and Administration (“GA”) expense and Sales and Marketing (“SM”) expense.

RD expense in the three- and six-month periods ended October 31, 2017 increased by $0.252 million and $0.305 million respectively over the same periods in the year prior, primarily due to an increase in synthesis and miscellaneous RD expenses, other costs, and salaries and benefits. These increases were partially offset by a decrease in clinical trial expenses.

GA expense in the three- and six-month periods ended October 31, 2017 decreased $0.181 million and $0.052 million respectively over the same period in the year prior, primarily due to reduction in professional fees, corporate governance, marketing and travel, and share-based compensation expense. These decreases were partially offset by an increase in salaries, benefits, rent and insurance.

SM expense in the three- and six-month periods ended October 31, 2017 decreased by $0.073 million and $0.095 million respectively compared to the same periods in the year prior due to a decrease in professional fees and marketing and travel. These decreases were partially offset by an increase in other SM expenses.

ITC income for the three- and six-month periods ended October 31, 2017 decreased by $0.039 million and $0.061 million respectively compared to the same periods in the year prior due to a decrease in eligible RD expenditures.

Financing

The Company executed on financing efforts during the quarter, closing two tranches of a non-brokered private placement with accredited investors in September and October 2017 for approximately $2.1 million in gross proceeds. As at October 31, 2017, the Company had cash, cash equivalents and investments of $1,246,852 and will need to obtain additional financing during the current fiscal year. Subsequent to the reporting quarter, the Company entered into an engagement with a U.S. investment bank in connection with proposed financing efforts in the U.S.

Detailed operating and financial results can be found in the Company’s Unaudited Condensed Interim Financial Statements and Management Discussion and Analysis for the three- and six-month periods ended October 31, 2017, which can be found on SEDAR at www.sedar.com or on the Company’s website at www.criticaloutcome.com.

About Critical Outcome Technologies Inc.

COTI is a clinical stage biotech company that uses proprietary artificial intelligence technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. COTI’s CHEMSAS® technology accelerates the discovery and development of novel drug therapies, allowing the Company to build a pipeline of potential drug candidates faster and with a higher probability of success than traditional methods.

The Company’s lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. P53 mutations occur in over 50% of all cancers. COTI-2 is initially being evaluated for the treatment of gynecologic cancers and head and neck squamous cell carcinoma in a Phase 1 clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University. The Company has secured orphan drug status in the United States for COTI-2 for the treatment of ovarian cancer. Preclinical data suggests that COTI-2 could dramatically improve the treatment of cancers with mutations in the p53 gene.

The Company’s second lead compound, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function. KRAS mutations occur in up to 30% of all cancers and represent a tremendous unmet clinical need and a desirable drug target. COTI-219 is undergoing IND-enabling studies to support a regulatory submission in 2018.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, visit www.criticaloutcome.com.

Notice to Readers:

Information contained in this press release may contain certain statements which constitute “forward- looking statements” as such term is defined under applicable securities laws. For example, the statements “These data support the potential for daily oral dosing and the continued development of COTI-2 as a potential treatment for patients” and “Subsequent to the reporting quarter, in December 2017, COTI announced pharmacodynamic (PD) data and positive signals of efficacy from the dose escalation portion of its Phase 1 trial of COTI-2 in gynecological malignancies, which suggest COTI-2 may be a potentially efficacious treatment for patients” and “The encouraging data readouts from the gynecological malignancies arm and the successful dosing of the first patient in our HNSCC expansion arm reinforce our confidence in COTI-2 as a potential treatment for a range of oncology indications” are forward-looking statements. Forward‐looking statements by their nature are not guarantees of future performance and are based upon management’s current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward‐looking statements. Management of COTI considers the assumptions on which these forward‐looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise. Except as required by law, COTI assumes no obligation to update forward-looking statements should circumstances or management’s expectations, estimates, projections and assumptions change.

Article source: http://www.otcmarkets.com/stock/COTQF/news?id=179218

Western Uranium Corp (WSTRF: OTCQX International) | Western Uranium Corporation Announces Closing of Non-Brokered Private Placement

TORONTO and NUCLA, Colo., Dec. 29, 2017 (GLOBE NEWSWIRE) — Western Uranium Corporation (CSE:WUC) (OTCQX:WSTRF) (“Western” or the “Company”) is pleased to announce the closing of a non-brokered private placement (the “Private Placement”) of 426,334 units (the “Units”) for gross proceeds of CAD$383,701, which remains subject to final regulatory approval.

The Company issued the Private Placement Units at a price of CAD$0.90 per Unit.  Each Unit consists of one common share of the Company (a “Share“) plus one half common share purchase warrant of the Company (each whole such warrant, a “Warrant”). Each Warrant shall entitle the holder to purchase one Share at a price of CAD$1.50 for a period of 24 months following the closing date of the Private Placement. A total of 426,334 Shares and 213,167 Warrants are being issued in this Private Placement.

Western intends to use the net proceeds from the Private Placement to fund the Company’s working capital and strategic initiatives.

In connection with the Private Placement, the Company paid CAD$2.079 in finder’s fees plus 2,310 compensation warrants exercisable for 24 months from the closing of Private Placement, each warrant being exercisable at CAD$1.50 per one Share of the Company.

Securities issued pursuant to the Private Placement shall be subject to a six month statutory hold period.

The securities offered and sold have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Western Uranium Corporation

Western Uranium Corporation is a Colorado based uranium and vanadium conventional mining company focused on low cost near-term production of uranium and vanadium in the western United States and development and application of ablation mining technology.

This news release may contain forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

George Glasier                                                                      
President and CEO                                                      
Office: 970-864-2125                                                
gglasier@western-uranium.com                                  

Russell Fryer
Executive Chairman
Office:  203-340-5633
rfryer@western-uranium.com

Primary Logo

Article source: http://www.otcmarkets.com/stock/WSTRF/news?id=179222

Fortress Paper Ltd. (FTPLF: OTCQX International) | Fortress Paper announces US$5,000,000 credit agreement

VANCOUVER, Dec. 29, 2017 /CNW/ – Fortress Paper Ltd. (“Fortress Paper” or the “Company“) (TSX:FTP) (OTCQX:FTPLF) reports that its wholly-owned subsidiary, Fortress Specialty Cellulose Inc. (“FSC“), has entered into a credit agreement with a private arm’s length lender, who will provide a secured revolving credit facility in the principal amount of up to US$5 million to FSC, subject to certain borrowing base restrictions (the “Loan“). The Loan will mature on December 30, 2020 and will accrue interest at a rate of LIBOR plus 5.75% per annum. The Loan is secured by FSC’s wood fibre inventory located at the FSC mill, consisting of round wood, wood chips, and dissolving pulp and excluding certain non-eligible inventory. FSC intends to use the proceeds of the Loan for general corporate purposes.

Fortress Paper Ltd. (CNW Group/Fortress Paper Ltd.)

About Fortress Paper

Fortress Paper operates its dissolving pulp business at the Fortress Specialty Cellulose Mill located in Canada, which has expanded into the renewable energy generation sector with the construction of a cogeneration facility.

This news release contains certain forward-looking information that reflects the current views and/or expectations of the Company with respect to its expectations, beliefs, assumptions, estimates, and forecasts about its business and the industry and markets in which it operates. The reader is cautioned that statements comprising forward-looking information are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other factors which are difficult to predict and that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on forward-looking information. Examples of such forward-looking information that may be contained in this news release include: the expected use of proceeds of the Loan. Persons reading this news release are cautioned that statements comprising forward-looking information are only predictions, and that the Company’s actual future results or performance are subject to certain risks and uncertainties including, without limitation: risks relating to changes in the market and other risk factors listed from time to time in the Company’s public filings. These risks, as well as others, could cause actual results and events to vary significantly. Accordingly, readers should not place undue reliance on statements comprising forward-looking information, which are qualified in their entirety by this cautionary statement. Fortress Paper does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking information, except as required by applicable securities law.

SOURCE Fortress Paper Ltd.

Article source: http://www.otcmarkets.com/stock/FTPLF/news?id=179223

WP Facebook Auto Publish Powered By : XYZScripts.com
Bunk Beds